Janus Henderson Group PLC Has $36.73 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Janus Henderson Group PLC trimmed its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,455,939 shares of the company's stock after selling 32,182 shares during the quarter. Janus Henderson Group PLC owned 4.33% of Immunome worth $36,726,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IMNM. JPMorgan Chase & Co. grew its holdings in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock valued at $359,000 after buying an additional 1,520 shares in the last quarter. Magnus Financial Group LLC grew its holdings in Immunome by 107.8% in the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock valued at $569,000 after buying an additional 27,777 shares in the last quarter. Scharf Investments LLC acquired a new position in Immunome in the 4th quarter valued at $471,000. Stoneridge Investment Partners LLC acquired a new position in Immunome in the 4th quarter valued at $123,000. Finally, Three Bridge Wealth Advisors LLC acquired a new position in Immunome in the 4th quarter valued at $293,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Up 0.8%

NASDAQ:IMNM opened at $7.97 on Thursday. The stock's 50-day simple moving average is $7.68 and its 200 day simple moving average is $9.88. The firm has a market capitalization of $693.49 million, a PE ratio of -0.98 and a beta of 2.00. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. The business had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $21.00 price objective (down from $33.00) on shares of Immunome in a report on Tuesday. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Lake Street Capital initiated coverage on Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price objective on the stock. Stephens reissued an "overweight" rating and set a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Guggenheim reduced their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $23.33.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 137,100 shares of Immunome stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. This represents a 20.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at $280,386. This represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 156,400 shares of company stock valued at $1,160,495 over the last ninety days. 8.60% of the stock is owned by corporate insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.